SSI Strategy

In the latest episode of our podcast, Christian Howell, Chief Commercial Officer at Cognito Therapeutics, shares his experience in implementing value-based healthcare models and offers unique perspectives on driving innovation while developing novel therapies. 🎙️ Learn about: 🔹 The importance of stakeholder engagement in healthcare innovation 🔹 Fostering a culture of smart risk-taking and learning from failures 🔹 Practical lessons for innovation from value-based healthcare models 🔗 Listen now: https://lnkd.in/dv-3YCRh

At SSI Strategy, our mission is clear: to Build Better Biotech companies by offering an alternative path to success. Maxwell Craig, SVP Business Consulting at SSI shares his thoughts. Building Better Biotechs means thinking with the end in mind. To me, this starts with building the value story of your therapy into the development life cycle as early as possible. Many times, companies get to their Phase 2 or Phase 3 trials and just start thinking about regulatory needs or the value they're going to present to payers. Then, they scramble to add things like real-world evidence studies or patient-reported outcomes at the last minute. However, they should really be thinking about precedents in the disease space that have come before. They should shape their development program in the most effective way to have as much clinical data as possible. This data should satisfy the needs of key stakeholders, including regulators, healthcare providers, patients, payers, and investors. Defining the value of your program early in development builds a platform for harmonization of strategy across the company and sets a north star that your program is striving toward. An early, aligned value story leads to effective and efficient drug development.

In this episode of our podcast, Dr. Thomas Lönngren, Strategic Advisor at SSI Strategy and former Executive Director of the European Medicines Agency, shares essential strategies for: 📌Engaging regulators effectively 📌 Designing market-oriented clinical trials 📌 Navigating global biotech development challenges With three decades of experience in drug regulation, Thomas provides valuable insights to help you avoid common pitfalls and optimize your path from concept to market. Click the link below to listen and learn from his expertise. https://lnkd.in/drfQ6jsq

Discover how applying behavioral science from the initial stages of drug development can be a game-changer for patient care. This article, published in Healthcare Business Today, features insights from William Hind and our Senior Director Lisa Campbell. It explores: 1️⃣ Understanding REAL patient priorities: How factors like administration methods significantly impact treatment adoption. 2️⃣ The power of early insights: How behavioral science can shape clinical development plans and design, leading to more patient-centric therapies. 3️⃣ Building a stronger commercial case: How incorporating patient priorities from day one strengthens your pitch to investors and stakeholders.   Read the full article here: https://lnkd.in/ezu9BAMS #PFDD #patientcentric #drugdevelopment #BehavioralScience #HealthcareInnovation

📌Only 2 days left! Have you registered for our webinar: "EU HTA Regulation: What’s changing & why it matters"? Our experts Dr Chantal W.M. van Gils & Dr Sigrid Klaar will be sharing insights into the New EU Health Technology Assessment (HTA) Regulation and the significant implications for the biotech and drug development sectors. 📅 Date: Thursday, 27th June 🕒 Time: 14:00 BST / 15:00 CEST / 09:00 EDT This session is designed to introduce you to the new regulation, its key components, and how it works. 🔗 Register Now: https://lnkd.in/eTwY_TTC hashtag #Webinar #HealthTech #EURegulation #Biotech #DrugDevelopment #HTA #RealWorldEvidence #Oncology #Pharma #Healthcare #MedicalResearch #IndustryExperts

At SSI Strategy, our mission is clear: to Build Better Biotech companies by offering an alternative path to success. Gabe Miller, Recruiting consultant at SSI shares his thoughts. To me, Building Better Biotechs means making biotech milestones feel less like moonshots. No one goes into biotech believing it's going to be easy; if anything, it's everything but. We make the jump into biotech because we're eternal optimists: we believe that new advancements in science & technology can pave pathways to new diagnostics, treatments & cures. We believe these advancements can improve the lives of patients with high unmet needs. At SSI, we're not just optimists, but pragmatic optimists. While we're guided by our ambitions to accelerate patient access to innovative care, we're grounded by our experiences & expertise to make that happen. For recruiting, that means bringing together the best & brightest biotech operators and business consultants to assemble agile teams that drive value in our clients' dynamic situations. We seek experienced operators who are not just experts in a given disease state, modality, or function, but who have demonstrated track records of building value in ambiguous environments. We look for experienced business consultants who are not just PowerPoint artists or Excel wizards, but who have proven abilities in building cogent strategies & operationalizing them with relentless execution. We learn from our failures, celebrate our wins, and share in the risk of building with our biotech clients because – ultimately – we believe in the work that we do. There's something special when the work becomes bigger than just oneself, and for recruiting, it's our goal to find others who share in that belief. It takes courage to build a biotech, and we all show up a little bit braver when we recognize that we don't have to do it alone.

📌Only one week left! Join us for this informative webinar: "EU HTA Regulation: What’s changing & why it matters!". Our experts Dr Chantal W.M. van Gils & Dr Sigrid Klaar will be sharing insights into the New EU Health Technology Assessment (HTA) Regulation and the significant implications for the biotech and drug development sectors. 📅 Date: Thursday, 27th June 🕒 Time: 14:00 BST / 15:00 CEST / 09:00 EDT This session is designed to introduce you to the new regulation, its key components, and how it works. 🔗 Register Now: https://lnkd.in/eTwY_TTC #Webinar #HealthTech #EURegulation #Biotech #DrugDevelopment #HTA #RealWorldEvidence #Oncology #Pharma #Healthcare #MedicalResearch #IndustryExperts

Recognizing Juneteenth Freedom Day, we honor the end of slavery in the U.S., celebrating the strength and resilience of the Black community, essential in driving our innovation and fostering a culture where every voice propels us toward a more just and inclusive future.

👋Hello from the DIA Global Annual Meeting in San Diego! Are you attending or happen to be in the area? Heather Paden & Brendan Slagle would love to connect with you. Looking forward to meeting you. 

✨ Building Better Biotechs: Insights from Our Medical Team✨ At SSI Strategy, our mission is clear: to Build Better Biotech companies by offering an alternative path to success. But what does "Building Better Biotechs" mean to our Medical team? Our SVP Medical, Delphine Moreau, shares her thoughts. When I think about what it means to Build Better Biotechs, I always come back to the idea of developing fit-for-purpose medical capabilities as a solid foundation for success. As a SVP of the Medical team at SSI Strategy, I’ve seen firsthand the challenges companies face when they build their medical teams too late, too small, or conversely, too big, often with misguided head office/field ratios. That’s why our medical team works closely with our clients to develop tailored, scalable workforce plans and medical strategies that align with their company’s stage and evolving priorities. We bring our expertise to help them establish the right medical team at the right time, develop robust medical strategies, and create effective communication materials that resonate with stakeholders and clearly convey the value of their therapies. But building strong medical capabilities isn’t just about having the right people and plans in place. It’s also about ensuring seamless collaboration with other functions across the company. From clinical development to pharmacovigilance, quality, regulatory, and commercial, we help our clients break down silos and foster a culture of collaboration and information sharing. When everyone works together towards a common goal, the scientific narrative of the company and its assets becomes truly cohesive and compelling. At the end of the day, what drives me and my team is knowing that we’re helping our clients bring life-changing therapies to patients faster and more efficiently. By helping them build strong medical capabilities, we’re not just supporting their success – we’re accelerating it, helping them meet their commitments to patients and investors more quickly.